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Abstract:
Non-alcoholic fatty liver disease (NAFLD) is a clinical entity of high prevalence in the world characterized by
fatty infiltration of liver tissue in the absence of alcohol consumption. The natural history of the disease de-
velops in successive phases reflected in different histological stages, with 10–20% of patients developing liver
cirrhosis and fibrosis. Fibrosis is a basic connective tissue lesion defined by the increase of the fibrillary extra-
cellular matrix (ECM) components in a tissue or organ. Matrix metalloproteinases (MMPs) constitute a family
of endopeptidases, which are involved in ECM and basement membranes components degradation. Fibrogenic
process is characterized by altered ECM composition, associated with modifications in MMPs behavior. The
active cross-talk between adipose tissue and liver can be altered in pathologies associated to insulin resistance
(IR), such as NAFLD. The role of adipokines on MMPs behavior in the liver could be partly responsible of liver
damage during IR. The aim of this revision is to describe the behavior of MMPs in NAFLD and its role in the
associated fibrosis.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is a clinical entity of high prevalence in the world (10–40%), character-
ized by fatty infiltration of liver tissue (>5% of hepatocytes) in the absence of alcohol consumption. It clusters a
morphological spectrum of disorders ranging from simple triglycerides (TG) accumulation in hepatocytes (hep-
atic steatosis; HS) to other entities of worse prognosis like non-alcoholic steatohepatitis (NASH), characterized
by steatosis, lobular inflammation and hepatocellular ballooning injuring. The natural history of the disease de-
velops in successive phases reflected in different histological stages, with 10–20% of patients developing liver
cirrhosis and fibrosis [1]. Parenchymal and non-parenchymal cells that constitute the functional architecture of
the liver are supported by an extracellular matrix (ECM) composed of fibrous proteins and proteoglycans. The
behavior and composition of ECM modulates the morphological organization and physiological function of the
liver thus, dysregulation of ECM homeostasis is associated with degenerative liver diseases. The maintenance
of the composition and function of the ECM is regulated by a family of zinc-dependent endopeptidases called
metalloproteinases (MMPs) [2].
NAFLD is considered the hepatic manifestation of metabolic syndrome (MS) and is closely related to in-
sulin resistance (IR) and cardiovascular disease (CVD) [3]. In the recent years, NAFLD has emerged as the most
prevalent chronic liver disease, due to the global obesity epidemic [4]. NAFLD results from complex interac-
tions between genetic, hormonal and nutritional factors, being obesity and MS the most important risk factors
identified until now [5]. The active cross-talk between adipose tissue and liver can be altered in these situations.
It is well known that the increase in circulating proinflammatory adipokines promotes liver disease. The role
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of these adipokines on MMPs behavior in the liver could be partly responsible for liver damage during IR and
obesity.
The aim of this revision is to describe the behavior of MMPs in NAFLD and its role in the associated fibrosis.
Metalloproteinases
MMPs constitute a family of more than 25 zinc-dependent endopeptidases, which are involved in ECM and
basement membranes components’ degradation [2]. The ECM is a multimolecular complex structure compris-
ing collagen and elastin fibers, structural glycoproteins including fibronectin and laminin, and mucopolysac-
charides. It is organized into a three-dimensional (3D) network and in physiological states a balance between
synthesis, deposit and degradation of ECM components exist [6]. According to their substrate specificity, MMPs
can be divided into five major groups: collagenases, stromelysins, matrilysins, gelatinases and membrane-type
MMPs [7]. These enzymes are expressed in different cell types including fibroblasts, neutrophils, monocytes,
macrophages and endothelial cells. MMPs are multidomain enzymes that have several similar structural do-
mains including cysteine-switch motif (PRCGXPD) in their propeptide, which maintain MMPs in the zymogen
form (pro-MMPs), the catalytic zinc-binding domain (HEXGHXXGXXHS) and the hemopexin-like domain [8].
MMPs are regulated at different levels such as gene transcription, zymogen activation and enzyme secretion
as well as by endogenous specific tissue inhibitors (TIMPs) [2]. Some MMPs are expressed constitutively, while
others are only expressed under specific stimuli, such as reactive oxygen species (ROS), pro-inflammatory cy-
tokines [interleukin (IL-1) and tumor necrosis factor alpha (TNF-α)] or by the contact of inflammatory cells
with the collagen of the ECM. They are secreted as latent zymogens (pro-MMPs) which are inactive due to
the interaction of the zinc ion in the catalytic domain with the sulfhydryl group of the Cys residue in the
prodomain. Pro-MMPs are activated by the disruption of the cysteine switch by different mechanisms such
as the proteolytic action of other proteases, conformational changes generated by nitric oxide (NO) and ROS,
or by chaotropic agents and denaturants such as sodium dodecyl sulfate, low pH and heat treatment, among
others. When this occurs the -SH group is replaced by H2O and the enzyme gains the ability to hydrolyze the
propeptide for its complete activation [9].
With reference to protein specific inhibitors, there are at least four members of TIMP family that form tight
inhibitory 1:1 complexes with MMPs. The balance between activated MMPs and TIMPs determines the net
result of MMPs activity in tissues. However, in pathological situations, this balance might be disrupted leading
to MMPs uncontrolled activation [10].
Among the physiological processes, MMPs are involved in organogenesis, angiogenesis, apoptosis, cell pro-
liferation and motility. Any disruption in MMPs regulation could lead to the development of diseases such as
cancer, rheumatoid arthritis, atherosclerosis, obesity, fibrosis and endometriosis [11], [12].
Previous studies have reported the behavior of different MMPs in IR states in humans [13], [14] and animal
models [15]. It has been observed that circulating MMPs are increased in patients with MS [13], [16] meanwhile
controversial results have been described in in vitro studies and in animal models [15], [17].
Fibrosis in NAFLD
Fibrosis is a connective tissue lesion defined by the increase of the fibrillary ECM components. One-third of
patients with NAFLD progress to liver fibrosis in 4–5 years after the first liver biopsy. It is important to mention
that recent studies have reported that advanced fibrosis in NAFLD predicts not only liver-related mortality but
also increased mortality due to cardiovascular events [18].
In healthy liver, hepatic stellate cells (HSCs), localized in the perisinusoidal space, are the most important
source of ECM. Upon chronic damage to liver tissue, HSCs activate and differentiate into fibroblast-like phe-
notype, increasing ECM deposition. Mediators released from damaged hepatocytes, such as lipid peroxidation
products and ROS, as well as activated Kupffer cells are important effectors driving HSC activation [19]. After
chronic inflammatory processes, hepatic fibrosis develops leading eventually to cirrhosis or liver cancer. This
process may result from an imbalance between enhanced matrix synthesis by HSCs and diminished breakdown
of connective tissue proteins. The hepatic fibrogenesis process takes place in two phases, the first one is char-
acterized by inflammation produced by fat accumulation in the liver as TG, increasing liver lipotoxicity. This
process activates hepatocytes and recruits T-cells, while biliary epithelial cells activates Kupffer cells. The result
is the increase in oxidative stress and the production of free radicals as well as other soluble factors, such as
transforming growth factor beta (TGF-β), capable of stimulating HSCs. In the second fibrotic phase, quiescent
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HSCs turn into myofibroblasts and lead to the apoptosis of hepatocytes, inducing the accumulation of fibrotic
cells. These cells induce immune cells recruitment, which are responsible of chronic inflammation [19], [20].
The fibrogenic process is associated with MMPs/TIMPs imbalance, which causes excessive accumulation
of ECM components [20].
MMPs and fibrosis
The fibrogenic process is characterized by ECM alterations, associated with MMPs/TIMPs imbalance [6]. In
the human liver, different MMPs and TIMPs are expressed [19], being MMP-2 and MMP-9 that are of great
importance in hepatic fibrosis. It has been demonstrated that variations in MMPs expression correlate with the
fibrotic stage of liver diseases [21]. Until now, the behavior of MMPs in the liver fibrosis process is controversial.
Previous studies reported increased collagenase activity in the early stage of liver fibrosis and reduced colla-
genase activity in advanced stages [22]. In our laboratory, we studied the behavior of circulating and hepatic
MMP-2 and -9 activity in patients with biopsy-proven NAFLD. In NAFLD patients, MMP-2 plasma activity
was increased in the severe fibrosis stage independently of the steatosis grade. However, liver MMP-2 activity
was decreased compared to non to moderate fibrosis patients (Figure 1). Previously, Hemman et al. reported
that in activated HSCs, TIMP-1 expression is increased and concomitantly MMPs activity is reduced, leading to
protein accumulation [21]. Meanwhile, in human liver biopsies, no difference in MMP-9 activity was observed
in steatosis situations. Wanninger et al. demonstrated that in human fatty liver MMP-9 activity is associated
with hepatic inflammation and fibrosis but not with hepatic steatosis and body weight [23].
Figure 1: MMP-2 plasma and liver activity in (A) control and NAFLD group. *p < 0.001. (B) Fibrosis stages in NAFLD
group. **p < 0.049. RU means relative units. (C) MMP-2 liver activity in non-to-moderate fibrosis (F0–F2) and severe fibro-
sis (F3–F4) group. ***p = 0.024.
Anyway, there are few studies analyzing the role of MMPs in NAFLD, and most of them studied mRNA
levels, but even their expression pattern remains controversial.
IR is frequently linked with hepatic fibrosis; thus, hyperinsulinemia may condition MMPs behavior [24].
In individuals with IR without NAFLD, we have previously demonstrated an increase in circulating MMP-2
activity, associated with a more atherogenic lipid profile [13], [25]. Similar results were also observed in patients
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with NAFLD, and positive associations between MMP-2 plasma activity and body mass index (BMI), waist
circumference and atherogenic lipoprotein profile were found (Table 1).










Spearman’s or Pearson’s tests according to data distribution. BMI, Body mass index; chol, cholesterol; TG, triglycerides; WC, waist
circumference.
MMPs and adipocytokines in fibrosis
Adipocytokines are polypeptides synthesized and secreted by adipose tissue which exerts autocrine, paracrine
and endocrine functions. Through these molecules adipose tissue directly connects with the liver, exerting mod-
ulatory effects. A continuous dynamic cross-talk between adipokines and liver exists, resulting in a beneficial
or unfavorable final effect [26]. During the expansion of adipose tissue, the adipocytokines profile is modified,
contributing to the development of hepatic steatosis and to the progression to NASH [27].
In IR and related disorders most of the proinflammatory adipocytokines, such as leptin, IL-6 and TNF-
α, are upregulated, while anti-inflammatory adipocytokines levels, such as adiponectin, are decreased. This
imbalance promotes susceptibility to metabolic and inflammatory diseases. Leptin and adiponectin are the
main cytokines synthesized in adipose tissue and exhibit different functions and opposite effects on the liver
[28] (Figure 2).
Figure 2: Role of metalloproteinases in the pathophysiology of non-alcoholic fatty liver disease and liver fibrosis in in-
sulin resistance.
The increase in circulating proinflammatory adipocytokines and the decrease in adiponectin levels lead to an imbalance
in metalloproteinases and their inhibitors, which contributes to the development of fibrosis. ECM, extracellular matrix;
HSC, hepatic stellate cells; IL-6, interleukin 6; MMPs, metalloproteinases; NAFLD, non-alcoholic fatty liver disease; TG,
triglycerides; TIMPs, tissue inhibitors of metalloproteinases; TNFα, tumor necrosis factor alpha.
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Leptin
Leptin is mainly produced by matured adipocytes, and it is secreted proportionally to the amount of white
adipose mass. Different studies have demonstrated the importance of leptin in NAFLD. Knock-out mice for
the ob gene (ob/ob), which codes for leptin, exhibit hepatic steatosis and NASH together with IR, obesity and
diabetes [26]. In animal models, it has been demonstrated that leptin may protect from hepatic steatosis at
the initial stages of the disease inhibiting gluconeogenesis, lipogenesis, and stimulating β-oxidation in liver.
However, with the disease progression, it may act as an inflammatory and fibrogenic factor [29]. Leptin is also
secreted by activated HSCs and, through an autocrine effect, promotes cells perpetuation and the synthesis
of the α1(I) and α2(I) fibrils, major components of dense and fibrotic ECM [30]. In parallel, in the liver, leptin
stimulates the production of TIMP-1 and represses the expression of MMP-1 [26], [31] (Figure 2). Accordingly,
the increase in leptin expression in NAFLD would favor hepatic inflammation and fibrosis.
Adiponectin
Adiponectin is an anti-inflammatory adipocytokine, which increases free fatty acid (FFA) oxidation and
decreases gluconeogenesis in the liver, improving insulin sensitivity. Therefore, adiponectin presents anti-
steatotic effects on the hepatocytes, protecting liver from steatosis. However, opposite to other adipokines,
adiponectin is paradoxically decreased in obesity. Therefore, it has been demonstrated that adiponectin serum
levels are reduced and inversely associated with the degree of hepatic steatosis, necroinflammation and fi-
brosis in NAFLD [32], [33]. Furthermore, adiponectin exerts anti-fibrotic action reducing HSC activation and
proliferation and inducing apoptosis.
Regarding the possible adiponectin influence on hepatic MMPs, in vitro studies reported that adiponectin
would increase MMP-9 activity in primary human hepatocytes [22]. Moreover, Saxena et al. demonstrated that
in liver adiponectin downregulates TGF-β, connective tissue growth factor and collagen, and favors matrix
degradation by changing the molecular ratio MMP-1/TIMP-1, explaining its anti-fibrotic action [30] (Figure
2). Otherwise, in patients with combined hyperlipidemia, it was reported that adiponectin decreases MMP-2,
MMP-9, TIMP-1 and TIMP-2 plasma levels [34]. In accordance, we previously reported an inverse association
between plasma adiponectin levels and circulating MMP-2 activity in patients with MS [14] as well as in NAFLD
patients, independently of obesity markers. In patients with NAFLD we also observed a negative correlation
between MMP-2 plasma activity and circulating adiponectin levels (Table 1), suggesting a positive regulatory
role of this adipocytokine on MMPs behavior.
Expert opinion
Different studies have shown that MMPs expression and activity are altered in insulin resistant states. Several
factors such as adipokines are involved in the regulation of these enzymes and their inhibitors. It must be taken
into account that there are different MMP expression patterns, thus the response to IR is variable in the diverse
tissues. This feature is partially responsible for the contradictory results reported until now. In the liver MMPs
exert a pro-fibrotic effect under various pathological conditions, such as NAFLD. However, it depends on the
stage of the disease and the consequent impact of different regulators on these enzymes and their inhibitors.
The consideration of MMPs as a therapeutic target for liver disease still requires further studies of their behavior
in patients with different steatosis degrees.
Outlook
The epidemic of obesity and IR in the world during the last decades has been responsible for the incredible
increase in the incidence and prevalence of NAFLD. Moreover, as a consequence of the lack of therapeutic
treatment a significant progression towards NASH and fibrosis is reported. Different drugs used in the man-
agement of IR, such as metformin and thiazolidinediones, have shown an inhibitory effect on MMPs in vitro;
however, studies in humans have reported controversial results. It could be due to the unspecific effect of these
drugs on the different MMPs and the time of inhibition. The principal challenge of much research nowadays
is the design of new specific drugs against different therapeutic targets, including MMPs and TIMPs, which
could be used since the beginning of the pathology to prevent NAFLD progression.
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Highlights
• Variation in MMPs expression is associated with the fibrotic stage of liver diseases.
• The behavior of MMPs in liver fibrosis process is controversial.
• Patients with NAFLD present higher MMP-2 plasma activity than controls.
• Patients with severe fibrosis present increased MMP-2 plasma activity and decreased MMP-2 liver activity.
• Different adipokines, such as adiponectin would be responsible for MMPs behavior.
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